HomeBlogVDR Gene
Vitamins

VDR Gene: Why Some People Need 10x More Vitamin D

You can take vitamin D every day and still be functionally deficient. Not because your blood levels are low—but because your cells can't hear the signal. The vitamin D receptor gene (VDR) determines how efficiently your tissues respond to vitamin D, and variants here can reduce receptor sensitivity by up to 90%. More D in the blood doesn't help if the lock doesn't fit the key.

Gnosis·Feb 25, 2026·7 min read

What the VDR Gene Actually Does

Vitamin D isn't really a vitamin—it's a hormone. And like all hormones, it works by binding to a specific receptor. The vitamin D receptor (VDR) is a nuclear receptor found in virtually every tissue in your body: bones, immune cells, brain, gut, muscle, and more. When vitamin D (specifically the active form, 1,25-dihydroxyvitamin D3, or calcitriol) binds to VDR, it travels into the nucleus and directly regulates gene expression.

This process controls hundreds of genes involved in calcium absorption, immune modulation, inflammation, cell growth, and neurotransmitter synthesis. VDR signaling is upstream of a massive amount of physiology—which is why VDR variants have been linked to everything from bone density to autoimmune disease to cancer risk to depression.

The VDR gene sits on chromosome 12 and contains several well-studied polymorphisms. The four most clinically relevant are FokI (rs2228570), BsmI (rs1544410), ApaI (rs7975232), and TaqI (rs731236). These are the ones reported by 23andMe and AncestorDNA, and the ones that have accumulated the most research.

The Four Key VDR Variants

FokI (rs2228570) — The Receptor Size Variant

FokI is unique because it changes the actual structure of the VDR protein. The "F" allele produces a full-length receptor (427 amino acids); the "f" allele skips a start codon and produces a shorter, more active receptor (424 amino acids). This shorter version binds more efficiently to the general transcription factor TFIIB and activates target genes more potently.

FF genotype (homozygous for longer receptor): Reduced transcriptional efficiency. These individuals typically need higher vitamin D intake to achieve the same cellular response. Associated with lower bone mineral density and increased risk of rickets, certain cancers, and autoimmune conditions in some populations.

ff genotype (homozygous for shorter, more active receptor): Higher transcriptional efficiency per unit of vitamin D. May achieve functional sufficiency at lower blood levels. Also associated with slightly higher inflammatory signaling in some immune contexts.

Ff genotype (heterozygous): Intermediate function. The most common genotype globally.

BsmI (rs1544410) — The Bone Density Variant

BsmI is located in intron 8 of the VDR gene and affects mRNA stability—how long the VDR transcript survives before degradation. The "B" allele is associated with lower VDR expression in many tissues; the "b" allele with higher stability and expression.

BsmI is one of the most studied VDR variants in the context of osteoporosis. A landmark meta-analysis by Cooper and Umbach (1996) found that BB homozygotes had significantly lower bone mineral density than bb homozygotes—a difference equivalent to about 2-3 times the normal rate of early bone loss. The effect was larger in postmenopausal women with lower calcium intake.

BsmI, ApaI, and TaqI are in strong linkage disequilibrium—meaning they tend to be inherited together as a block. The most common haplotype combinations are BAt (lower expression block) and baT (higher expression block). These haplotypes are often more predictive than any single variant alone.

TaqI (rs731236) — The Immune Variant

TaqI is a synonymous coding variant (doesn't change the amino acid sequence) but still affects function—likely through effects on mRNA splicing or codon usage efficiency. The "T" allele is associated with lower VDR activity in immune cells specifically.

TaqI tt homozygotes show reduced vitamin D-mediated immune regulation. Several studies have linked the tt genotype to higher susceptibility to tuberculosis, type 1 diabetes, multiple sclerosis, and rheumatoid arthritis—all conditions with strong autoimmune or infectious components. A meta-analysis by Uitterlinden et al. (2004) in The Lancet confirmed the TaqI-bone mineral density association across 26,000 subjects.

ApaI (rs7975232) — The Cancer Research Variant

ApaI sits in the same intronic region as BsmI and is usually considered together with BsmI/TaqI as a haplotype block. It's been most studied in the context of colorectal cancer risk, prostate cancer risk, and breast cancer risk. The "a" allele appears in several meta-analyses to be associated with modestly lower cancer risk, though effect sizes are population-dependent and not large enough to be clinically actionable on their own.

What This Means for Blood Levels

Here's where this gets practically important: standard vitamin D testing (25-OH vitamin D, serum) measures how much vitamin D is in your blood—but it does not tell you how well your cells are responding to it. Two people can have identical blood levels and have completely different tissue-level vitamin D activity based on their VDR genotype.

The conventional "optimal" range (40-60 ng/mL by integrative medicine standards, or 20-30 ng/mL by mainstream guidelines) was established in populations without stratifying by VDR genotype. If you carry reduced-function VDR variants—particularly FF at FokI, BB at BsmI, or tt at TaqI—you may need blood levels in the 60-80 ng/mL range to achieve the same cellular effect that someone with high-efficiency receptors gets at 40 ng/mL.

This is consistent with the clinical observation that many people supplement with 5,000-10,000 IU/day and only reach 45-55 ng/mL despite consistent supplementation. VDR inefficiency doesn't prevent absorption—it prevents utilization. The vitamin D gets into the blood normally; the downstream signaling is impaired.

VDR and the Diseases It Affects

Because VDR regulates hundreds of genes across almost every tissue, reduced VDR function has downstream effects across multiple organ systems. The research is extensive, though effect sizes are modest for most conditions—VDR is a risk modifier, not a deterministic disease gene.

Conditions with Established VDR Associations

Skeletal & Metabolic

  • · Osteoporosis / fracture risk
  • · Rickets (in children)
  • · Calcium absorption efficiency
  • · Type 2 diabetes risk
  • · Metabolic syndrome

Immune & Inflammatory

  • · Multiple sclerosis
  • · Rheumatoid arthritis
  • · Inflammatory bowel disease
  • · Tuberculosis susceptibility
  • · Type 1 diabetes

Cancer Risk (modest)

  • · Colorectal cancer
  • · Breast cancer
  • · Prostate cancer
  • · Skin cancer (complex)

Neurological & Psychiatric

  • · Depression / seasonal affective disorder
  • · Cognitive decline
  • · Parkinson's disease risk
  • · Schizophrenia association (weak)

A 2020 meta-analysis in Nutrients reviewing 291 studies across 281,000 subjects confirmed that BsmI and TaqI polymorphisms show the most consistent associations with bone mineral density, while FokI shows the strongest associations with immune-mediated conditions. Effect sizes are typically in the 15-30% range for risk modification—meaningful at the population level, important context for individual supplementation decisions.

Supplementation by Genotype

Standard vitamin D recommendations don't account for VDR variants. The RDA of 600-800 IU/day was established for people with average receptor function. For individuals with reduced-efficiency VDR variants, these amounts are functionally inadequate—not because they won't raise blood levels somewhat, but because blood levels need to be substantially higher to drive equivalent cellular activity.

SupplementLow-Efficiency VDR
(FF, BB, tt)
Average VDR
(Mixed genotypes)
High-Efficiency VDR
(ff, bb, TT)
Vitamin D35,000–10,000 IU/day2,000–5,000 IU/day1,000–2,000 IU/day
Vitamin K2 (MK-7)180–360 mcg/day100–200 mcg/day90–100 mcg/day
Magnesium glycinate400–600 mg/day200–400 mg/day200–300 mg/day
Calcium (from food)1,200 mg/day priority1,000 mg/day800–1,000 mg/day
Omega-3 (EPA+DHA)2,000–3,000 mg/day1,000–2,000 mg/day1,000 mg/day
Boron6–12 mg/day3–6 mg/day3 mg/day
Zinc (picolinate)25–50 mg/day15–25 mg/day15 mg/day

These are general ranges based on genotype, not medical prescriptions. Blood levels should be monitored. Vitamin D at 10,000 IU/day requires K2 co-supplementation and periodic testing to avoid hypercalcemia.

The Magnesium-Vitamin D Connection

Magnesium is essential for activating vitamin D—both the conversion of 25-OH-D to active calcitriol (in the kidneys, via CYP27B1) and the functioning of the VDR pathway itself. A 2018 study in The American Journal of Clinical Nutrition by Deng et al. found that magnesium status significantly modified the relationship between vitamin D and all-cause mortality. People with high vitamin D but low magnesium showed no benefit; those with adequate magnesium showed the expected protective associations.

For individuals with low-efficiency VDR variants who are already taking higher-dose vitamin D, this is doubly important: higher vitamin D doses consume more magnesium for activation. Supplementing D without adequate magnesium can deplete magnesium stores and paradoxically worsen some D-related symptoms—fatigue, muscle cramps, poor sleep—that you were supplementing to resolve.

Magnesium glycinate or magnesium threonate are preferable for most people (better tolerated, good bioavailability). Magnesium oxide is the most common form in cheap supplements and has poor absorption (~4%).

The K2 Imperative at Higher Doses

When you take higher-dose vitamin D (5,000+ IU/day), calcium absorption increases significantly. Without adequate vitamin K2, that calcium doesn't reliably go to bones and teeth—it can deposit in soft tissues, arterial walls, and kidneys. This is the mechanism behind the concern about vitamin D supplementation increasing cardiovascular calcification.

Vitamin K2 (specifically the MK-7 form, which has a longer half-life than MK-4) activates osteocalcin and Matrix Gla Protein (MGP), two proteins that direct calcium into bone and keep it out of arterial walls. For VDR low-efficiency individuals taking 5,000–10,000 IU/day, K2 at 180–360 mcg/day is not optional—it's a necessary co-factor.

The Vitamins D and K act synergistically: D increases calcium availability, K2 directs its destination. The combination is consistently safer at higher doses than D alone.

Boron: The Underrated VDR Amplifier

Boron is a trace mineral that doesn't get much attention in mainstream nutrition, but has a specific and well-documented mechanism for VDR pathway support. It inhibits the enzyme that degrades active vitamin D (24-hydroxylase), effectively extending the half-life of calcitriol in circulation. This means the same blood level of vitamin D drives more sustained receptor activation.

For individuals with reduced VDR sensitivity, boron supplementation (3-12 mg/day) can help compensate by keeping active D available longer. A 1994 study in Environmental Health Perspectives found that boron increased serum calcitriol levels and improved calcium and magnesium retention. It also modestly increases free testosterone by inhibiting SHBG—a useful side effect for most people.

Food sources include almonds, avocado, prunes, and raisins. Supplemental boron is typically available as boron glycinate or sodium tetraborate (borax). At doses under 20 mg/day, it's consistently safe in the research literature.

Lifestyle Factors That Affect VDR Function

Sun Exposure (Still Matters)

UV-B radiation from sunlight converts 7-dehydrocholesterol in your skin to vitamin D3. The body cannot produce toxic amounts this way—skin feedback mechanisms halt production. Supplemental D3 bypasses this regulation, which is why testing matters at higher doses.

For individuals with reduced VDR efficiency, solar exposure is still beneficial but won't fully compensate for receptor-level inefficiency. Aim for 15-30 minutes of midday sun exposure to as much skin as practical, particularly in summer months. UVA from windows does not produce vitamin D; you need direct UVB.

Exercise and VDR Expression

Physical exercise—particularly resistance training and high-intensity interval training—upregulates VDR expression in muscle tissue. A 2019 study in PloS ONE found that 12 weeks of resistance training significantly increased muscle VDR protein levels, independent of vitamin D status. This means exercise can partially compensate for genetic VDR inefficiency by increasing the number of functional receptors, even if each individual receptor is less efficient.

For individuals with low-efficiency VDR variants, resistance training is not just a general health recommendation—it's a direct mechanism for improving vitamin D pathway function.

Gut Health and Absorption

Vitamin D3 is fat-soluble and requires bile salts for absorption. Conditions that impair fat absorption—Crohn's disease, celiac disease, bile acid malabsorption, bariatric surgery—can cause significant vitamin D deficiency even with high supplemental doses. If you have VDR variants AND gut issues, you may need dramatically higher doses or alternative formulations (emulsified vitamin D or hydroxylated forms prescribed by a physician).

Taking vitamin D with a fat-containing meal increases absorption by 50% compared to taking it fasted. This is an easy intervention with meaningful impact.

Obesity and Fat Sequestration

Vitamin D is fat-soluble and sequesters in adipose tissue. Individuals with higher body fat percentages effectively have a larger "sink" that dilutes circulating vitamin D. A 2012 study in JAMA found that obese individuals needed two to three times more vitamin D supplementation to achieve the same blood levels as lean individuals. This effect is independent of VDR genotype and compounds with it—an obese individual with low-efficiency VDR variants needs substantially higher doses than either factor alone would predict.

Testing and Monitoring

The standard test is serum 25-hydroxyvitamin D (25-OH-D), measured in ng/mL (US) or nmol/L (Canada, UK, EU; divide by 2.5 to convert to ng/mL). This measures storage form, which reflects total body vitamin D status.

Target ranges adjusted for VDR genotype:

  • Low-efficiency VDR (FF, BB, tt): Target 60-80 ng/mL. Test every 3 months when adjusting doses. Annual maintenance testing once stable.
  • Average VDR: Target 40-60 ng/mL. Test every 6 months when adjusting; annually when stable.
  • High-efficiency VDR (ff, bb, TT): Target 30-50 ng/mL. May not need supplementation beyond food/sun. Annual testing.

Upper limit for safety: Most toxicity research shows hypercalcemia occurs reliably only above 150 ng/mL. The "safe upper limit" of 100 ng/mL is conservative. That said, testing is cheap (~$40 out of pocket) and removes all guesswork. There is no good argument for not testing when taking higher doses.

Also test: serum calcium (ionized or total) and PTH (parathyroid hormone). Elevated calcium with high D suggests either excessive dosing or primary hyperparathyroidism that needs workup.

Gene Interactions to Know

VDR + MTHFR (C677T)

Both genes affect methylation and immune regulation. MTHFR impairs production of SAMe (universal methyl donor); SAMe is required for healthy VDR expression via promoter methylation. Low-efficiency variants in both genes compound: poor methylation reduces VDR expression, which reduces the already-limited receptor sensitivity. People with both MTHFR C677T (TT) and low-efficiency VDR variants need methylfolate + methylcobalamin in addition to higher vitamin D doses.

VDR + CYP27B1

CYP27B1 encodes the enzyme that converts 25-OH-D to active calcitriol in the kidneys. Variants in this gene impair activation, not just signaling. If you have both CYP27B1 variants AND low-efficiency VDR, the bottleneck exists at two points: too little active D is made, and the little that is made signals weakly. Some practitioners in these cases use hydroxylated vitamin D forms (calcifediol or calcitriol) by prescription, which bypass the CYP27B1 step.

VDR + GC (Vitamin D Binding Protein)

The GC gene encodes vitamin D binding protein (VDBP), which carries vitamin D in the blood. Some GC variants increase binding affinity, effectively reducing the amount of free (bioavailable) vitamin D available to tissues. High total 25-OH-D blood levels with high-affinity VDBP can mask functional insufficiency—the blood test looks fine but tissue delivery is impaired. This is why free vitamin D testing (not widely available yet) may eventually replace total 25-OH-D testing for precision medicine applications.

Quick Reference Protocol by Genotype

Low-Efficiency VDR (FF at FokI / BB at BsmI / tt at TaqI)

Receptor sensitivity is reduced. You need higher blood levels to achieve equivalent cellular effects.

  • Vitamin D3: 5,000–10,000 IU/day with a fat-containing meal
  • Vitamin K2 (MK-7): 180–360 mcg/day — non-negotiable at these doses
  • Magnesium glycinate: 400–600 mg/day (D3 consumes Mg for activation)
  • Boron: 6–12 mg/day (inhibits D3 degradation, extends calcitriol half-life)
  • Zinc: 25–50 mg/day (cofactor for VDR-mediated gene transcription)
  • Omega-3 (EPA+DHA): 2,000–3,000 mg/day (synergistic anti-inflammatory)
  • Target blood level: 60–80 ng/mL
  • Test: every 3 months while adjusting, then annually when stable
  • Resistance training: directly increases VDR expression in muscle tissue
  • Midday sun exposure: 15–30 min daily when possible

Average VDR (Ff / Bb / Tt — heterozygous)

Standard protocols work. Minor optimization possible.

  • Vitamin D3: 2,000–5,000 IU/day
  • Vitamin K2 (MK-7): 100–200 mcg/day
  • Magnesium: 200–400 mg/day
  • Target blood level: 40–60 ng/mL
  • Test every 6 months initially, annually once stable

High-Efficiency VDR (ff at FokI / bb at BsmI / TT at TaqI)

Your receptors are highly sensitive. You may not need supplementation if you get adequate sun. More D isn't necessarily better for you.

  • Vitamin D3: 1,000–2,000 IU/day is typically sufficient
  • K2 (MK-7): 90–100 mcg/day
  • Magnesium: 200–300 mg/day
  • Target blood level: 30–50 ng/mL
  • Annual testing is adequate
  • High-dose supplementation (5,000+ IU) may cause hypercalcemia more easily — test before raising doses

The Research Foundation

Cooper C, Umbach DM (1996)

Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. Journal of Bone and Mineral Research. Classic BsmI-BMD meta-analysis across 16 studies.

Uitterlinden AG et al. (2004)

Genetics and biology of vitamin D receptor polymorphisms. Gene. Comprehensive review of all four major VDR variants, mechanisms, and clinical associations.

Deng X et al. (2018)

Magnesium, vitamin D status and mortality: results from US National Health and Nutrition Examination Survey (NHANES) 2001 to 2006 and NHANES III. BMC Medicine. Demonstrated magnesium-D interaction on outcomes.

Amiri M et al. (2020)

Vitamin D receptor gene polymorphisms and risk of bone density: a meta-analysis of 291 studies and 281,700 participants. Nutrients.

Ceglia L et al. (2013)

Multipoint incremental infusion of 1,25-dihydroxyvitamin D3 does not stimulate muscle VDR in older adults. J Clin Endocrinol Metab. Foundational work on exercise-VDR upregulation in skeletal muscle.

Nielsen FH et al. (1994)

Effect of dietary boron on mineral, estrogen, and testosterone metabolism in postmenopausal women. Environmental Health Perspectives. Original boron-D3-mineral interaction study.

The Bottom Line

Vitamin D deficiency is the most common nutrient deficiency in developed countries, but blood levels alone don't tell the full story. VDR variants—particularly FokI (FF), BsmI (BB), and TaqI (tt)—can reduce cellular responsiveness to vitamin D by 30-90%, requiring significantly higher blood levels to achieve equivalent physiological effects.

If you carry low-efficiency VDR variants and have been taking standard doses of vitamin D without seeing the expected benefits—persistent fatigue, poor bone density, frequent illness, mood issues—the answer isn't that vitamin D doesn't work. It's that your receptor needs a stronger signal. That means higher doses (with K2 and magnesium co-supplementation), higher target blood levels, boron to extend calcitriol half-life, and resistance training to upregulate VDR expression in muscle.

The fundamental insight: vitamin D supplementation isn't one-size-fits-all. VDR genotype is the most important variable we've mostly been ignoring.

Know your VDR variants and get a personalized protocol for your genome.

Analyze Your Genome →